• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At DaVita (DVA) Valuation As Analyst Upgrades And AI Efforts Support Earnings Outlook

    Simply Wall St·04/06/2026 13:18:32
    Listen to the news

    Event driven focus on DaVita

    DaVita (DVA) is back on investor watchlists after fresh analyst estimate revisions pointed to higher earnings expectations, along with new AI driven efforts aimed at improving patient care and operational efficiency.

    See our latest analysis for DaVita.

    At a share price of US$145.58, DaVita has given investors a 26.9% 90 day share price return and a 76.03% three year total shareholder return. This suggests that recent momentum has built on a longer recovery trend as AI and earnings expectations stay in focus.

    If you are interested in how technology is reshaping healthcare, it may be worth widening your search to other AI focused names using our 37 healthcare AI stocks

    With DaVita trading around US$145.58, recent returns strong over 90 days and analyst targets only modestly higher, the key question is whether AI and earnings optimism leave upside on the table or if the market is already pricing in future growth.

    Most Popular Narrative: 4% Undervalued

    DaVita's most followed narrative places fair value at $151.71, slightly above the last close of $145.58. This frames the current AI and earnings debate around modest undervaluation rather than a stretch price.

    The aging population and rising rates of diabetes and hypertension continue to fuel steady underlying demand for dialysis, and management reaffirmed their belief in a return to 2% annual treatment growth over time, suggesting upside to revenue as volumes recover from temporary disruptions. Ongoing investments in technology, AI, and data analytics are driving structural cost reductions through improved operational efficiency and enhanced clinical outcomes, which management expects to support margin improvement even in periods of flat or negative volume growth.

    Read the complete narrative.

    Curious what sits behind that fair value gap to the current price? The narrative leans on steady top line expansion, firmer margins and a future earnings multiple that is more conservative than many US healthcare names. The exact mix of revenue growth, profitability and discount rate assumptions is where the story really gets interesting.

    Result: Fair Value of $151.71 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, you also need to weigh risks such as reimbursement updates that trail cost inflation and persistently high mortality, which could pressure volumes, margins and cash flow.

    Find out about the key risks to this DaVita narrative.

    Next Steps

    The mix of optimism around AI and earnings, alongside clear clinical and reimbursement risks, means opinions are split. Act quickly and review the details yourself, then weigh both sides by checking the 3 key rewards and 1 important warning sign

    Looking for more investment ideas?

    If DaVita has sharpened your focus on quality opportunities, do not stop here, use the Simply Wall Street Screener to uncover more stocks that might fit your approach.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.